Plan B: The Road Ahead
This article was originally published in The Tan Sheet
With at least 44,000 Plan B comments still under review at FDA, it is unclear when the agency will take its next step toward a decision on the proposed switch. In the meantime, those seeking OTC sale of EC are not keeping quiet on the issue. With lawsuits pending and pharmacy access to the drug increasing among individual states, there is plenty in store for Plan B in the coming year..
You may also be interested in...
Reports from FDA officials vary as to the timing of the decision not to approve Barr's emergency contraceptive Plan B for over-the-counter sale, GAO's investigation into the application process reveals (see chart: "1Brief Timeline of Major Plan B Events Related to the Initial OTC Switch Application").
Barr is testing a drugstore point-of-purchase program that directs consumers to ask their pharmacists about Plan B in states with pharmacy access to the emergency contraceptive
FDA Office of Women's Health Director Susan Wood is resigning over the agency's handling of Barr Labs' application to switch its Plan B emergency contraceptive over-the-counter